![]() These three drugs earned, respectively, $839m - up 23% year-on-year - $451m - up 33% year-on-year - and $63m - up 923% yoy - in 2022. Seagen markets and sells ADCETRIS, approved to treat Hodgkin's Lymphoma and T-cell Lymphoma, PADCEV, approved for Urothelial (bladder) cancer, and TIVDAK, approved for Cervical Cancer. The best known ADC drug developer - responsible for four of 12 ADCs approved for commercial use to date by the FDA - is Seattle based Seagen - formerly known as Seattle Genetics. These targeted agents combine the unique and very sensitive targeting capabilities of antibodies allowing sensitive discrimination between healthy and cancer tissues with the cell-killing ability of cytotoxic drugs. Mersana is a specialist in a specific field of drug development - antibody drug conjugates ("ADCs") - described as follows by :Īntibody-drug conjugates or ADCs are a new class of highly potent biopharmaceutical drug composed of an antibody linked, via a chemical linker, to a biologically active drug or cytotoxic compound. Mersana - An ADC Pioneer That Just Had Its Wings Clipped To explain why Mersana has been on such a roller-coaster ride and speculate about what direction it may move in next, it's necessary to take a step backward and study the path that the company - which enjoyed a >$1bn market cap valuation prior to today's sell-off - has been pursuing. Shares took flight at the beginning of May - rising from $3.7, to >$8 per share in less than one week. It may interest investors to know however that Mersana stock was trading at lower value less than two months ago. No cash balance or cash flow is included in the calculation.Mersana Therapeutics ( NASDAQ: MRSN) shares are in freefall - the stock price is down 58% today (at the time of writing), trading at a price of ~$4, owing to a partial clinical hold pausing new patient enrollment in the company's UP-NEXT and UPGRADE-A clinical trials of lead asset upifitamab rilsodotin in platinum-sensitive ovarian cancer. Please note all regulatory considerations regarding the presentation of fees must be taken into account. Backtested results are adjusted to reflect the reinvestment of dividends and other income and, except where otherwise indicated, are presented gross-of fees and do not include the effect of backtested transaction costs, management fees, performance fees or expenses, if applicable. Actual performance may differ significantly from backtested performance. Further, backtesting allows the security selection methodology to be adjusted until past returns are maximized. Since trades have not actually been executed, results may have under- or over-compensated for the impact, if any, of certain market factors, such as lack of liquidity, and may not reflect the impact that certain economic or market factors may have had on the decision-making process. Specifically, backtested results do not reflect actual trading or the effect of material economic and market factors on the decision-making process. ![]() Backtested performance is developed with the benefit of hindsight and has inherent limitations. This information is provided for illustrative purposes only. No representations and warranties are made as to the reasonableness of the assumptions. ![]() Certain assumptions have been made for modeling purposes and are unlikely to be realized. Changes in these assumptions may have a material impact on the backtested returns presented. General assumptions include: XYZ firm would have been able to purchase the securities recommended by the model and the markets were sufficiently liquid to permit all trading. Backtested results are calculated by the retroactive application of a model constructed on the basis of historical data and based on assumptions integral to the model which may or may not be testable and are subject to losses. The results reflect performance of a strategy not historically offered to investors and does not represent returns that any investor actually attained. Backtested performance is not an indicator of future actual results. Disclaimer: The TipRanks Smart Score performance is based on backtested results. ![]()
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |